Fw: Pleural mesothelioma: diagnostic problems and evaluation of prognostic factors.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:58 PM
Subject: Pleural mesothelioma: diagnostic problems and evaluation of prognostic factors.

[1]J Egypt Natl Canc Inst. 2006 Dec; 18(4): 303-10
Ismail HM, A Nouh MA, Abulkheir IL, Abd El-Rahman Ael-R, Tawfik HN

Background: Malignant pleural mesothelioma (MPM) in Egypt is mainly attributed to an environmental origin i.e exposure to asbestos, with a high incidence in women and young adults. Immunohistochemistry and ultrastructural features aid in the diagnosis. The p27Kip1 is a kinase inhibitor protein acting as a cell cycle regulator and a putative tumor suppressor gene playing a critical role in the pathogenesis of several human neoplasms. Aim: A clinicopathologic, immunohistochemical and ultrastructural study of mesothelioma in Egyptian patients, with identification of different prognostic factors. Material and Methods: Sixty-one cases of MPM were collected from the department of pathology at the NCI, Cairo. Cases were stained by monoclonal antibodies against CK5 /6, calretinin, vimentin, CD15, CEA and p27. Results: More than half (57.4%) of the patients were residents in endemic areas; 50.8% were of epithelioid type. CK5 / 6 was positive in 45 (73.8%) cases, 39 (63.9%) cases were positive for vimentin, 49 (80.3%) cases were positive for calretinin. One case showed a focal weak positive reaction to CD15. None of the cases stained for CEA. There was a statistically significant relation between p27 expression and the histopathologic type (p =0.02) between overall survival and age (p = 0.01), histopathologic type (p =0.02) and stage (p =0.006). Conclusion: MPM is an increasing disaster in Egypt which is underestimated and neglected. A panel of immunohistochemical markers should be used for proper evaluation. p27 has proven to be a potential biologic prognostic marker for mesothelioma and more studies as regard its significance are recommended on a larger number. Key Words: Mesothelioma - Asbestos - CK5 / 6 - Calretinin- p27.



___
Source: http://www.hubmed.org/display.cgi?uids=18301454
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

__________________________________________________
Do You Yahoo!?
Tired of spam? Yahoo! Mail has the best spam protection around
http://mail.yahoo.com

Fwd: Dedication of plaque in memory of 9/11 paramedic who died in '06

---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: Dedication of plaque in memory of 9/11 paramedic who died in '06
To: mesothelioma77@gmail.com


Newsday - Reeve died on March 16, 2006, of mesothelioma, a lung cancer associated with exposure to asbestos. The 41-year-old developed a cough in late 2003 and retired about a year later, too ill to work.

Tue, 11 Mar 2008 10:38:00 GMT

___
Source: http://www.newsday.com/news/local/wire/newyork/ny-bc-nyc--paramedicdeath0311mar11,0,3660973.story
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: W.R. Grace to Pay for Cleanup of Asbestos Contamination in Libby ...

---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: W.R. Grace to Pay for Cleanup of Asbestos Contamination in Libby ...
To: mesothelioma77@gmail.com


StreetInsider.com - Asbestos, a recognized human carcinogen, is known to cause lung cancer and mesothelioma, a lethal tumor of the lining of the chest and abdominal cavities.

Tue, 11 Mar 2008 21:22:00 GMT

___
Source: http://www.streetinsider.com/Press+Releases/W.R.+Grace+to+Pay+for+Cleanup+of+Asbestos+Contamination+in+Libby%2C+Montana/3450238.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Equitable Building asbestos case referred to A.G.

---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: Equitable Building asbestos case referred to A.G.
To: mesothelioma77@gmail.com


Des Moines Register - The DNR has accused Knapp and his crews of violating a list of state regulations meant to protect workers and the public from breathing asbestos fibers, which can scar lungs and cause cancer.

Tue, 11 Mar 2008 19:20:00 GMT

___
Source: http://www.desmoinesregister.com/apps/pbcs.dll/article?AID=/20080311/NEWS/80311024/1001
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fw: Transcriptome sequencing of malignant pleural mesothelioma tumors.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:58 PM
Subject: Transcriptome sequencing of malignant pleural mesothelioma tumors.

[1]Proc Natl Acad Sci U S A. 2008 Feb 26;
Sugarbaker DJ, Richards WG, Gordon GJ, Dong L, De Rienzo A, Maulik G, Glickman JN, Chirieac LR, Hartman ML, Taillon BE, Du L, Bouffard P, Kingsmore SF, Miller NA, Farmer AD, Jensen RV, Gullans SR, Bueno R

Cancers arise by the gradual accumulation of mutations in multiple genes. We now use shotgun pyrosequencing to characterize RNA mutations and expression levels unique to malignant pleural mesotheliomas (MPMs) and not present in control tissues. On average, 266 Mb of cDNA were sequenced from each of four MPMs, from a control pulmonary adenocarcinoma (ADCA), and from normal lung tissue. Previously observed differences in MPM RNA expression levels were confirmed. Point mutations were identified by using criteria that require the presence of the mutation in at least four reads and in both cDNA strands and the absence of the mutation from sequence databases, normal adjacent tissues, and other controls. In the four MPMs, 15 nonsynonymous mutations were discovered: 7 were point mutations, 3 were deletions, 4 were exclusively expressed as a consequence of imputed epigenetic silencing, and 1 was putatively expressed as a consequence of RNA editing. Notably, each MPM had a different mutation profile, and no mutated gene was previously implicated in MPM. Of the seven point mutations, three were observed in at least one tumor from 49 other MPM patients. The mutations were in genes that could be causally related to cancer and included XRCC6, PDZK1IP1, ACTR1A, and AVEN.



___
Source: http://www.hubmed.org/display.cgi?uids=18303113
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

---

Be a better friend, newshound, and know-it-all with Yahoo! Mobile. Try it now.

Fw: Transcriptome sequencing of malignant pleural mesothelioma tumors.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:58 PM
Subject: Transcriptome sequencing of malignant pleural mesothelioma tumors.

[1]Proc Natl Acad Sci U S A. 2008 Feb 26;
Sugarbaker DJ, Richards WG, Gordon GJ, Dong L, De Rienzo A, Maulik G, Glickman JN, Chirieac LR, Hartman ML, Taillon BE, Du L, Bouffard P, Kingsmore SF, Miller NA, Farmer AD, Jensen RV, Gullans SR, Bueno R

Cancers arise by the gradual accumulation of mutations in multiple genes. We now use shotgun pyrosequencing to characterize RNA mutations and expression levels unique to malignant pleural mesotheliomas (MPMs) and not present in control tissues. On average, 266 Mb of cDNA were sequenced from each of four MPMs, from a control pulmonary adenocarcinoma (ADCA), and from normal lung tissue. Previously observed differences in MPM RNA expression levels were confirmed. Point mutations were identified by using criteria that require the presence of the mutation in at least four reads and in both cDNA strands and the absence of the mutation from sequence databases, normal adjacent tissues, and other controls. In the four MPMs, 15 nonsynonymous mutations were discovered: 7 were point mutations, 3 were deletions, 4 were exclusively expressed as a consequence of imputed epigenetic silencing, and 1 was putatively expressed as a consequence of RNA editing. Notably, each MPM had a different mutation profile, and no mutated gene was previously implicated in MPM. Of the seven point mutations, three were observed in at least one tumor from 49 other MPM patients. The mutations were in genes that could be causally related to cancer and included XRCC6, PDZK1IP1, ACTR1A, and AVEN.



___
Source: http://www.hubmed.org/display.cgi?uids=18303113
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

---

Looking for last minute shopping deals? Find them fast with Yahoo! Search.

Fw: Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:58 PM
Subject: Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.

[1]Lung Cancer. 2008 Feb 25;
Metintas M, Ak G, Parspour S, Yildirim H, Erginel S, Alatas F, Batırel HF, Sivrikoz C, Metintas S, Dundar E

In malignant pleural mesothelioma (MPM) patients, local dissemination (LD) of the tumor is frequently observed at the sites of intervention where diagnosis/treatment are performed. We evaluate the factors affecting LD frequency and discuss the use of PR in MPM patients. Histopathologically diagnosed 212 MPM patients who had not received PR were evaulated in terms of development of LD. Of the 212 patients, 29 received supportive therapy, 157 received chemotherapy and 26 received multi-modal therapy. The LD frequency was 13.2% for all patients. The median survival rate was 9 or 10 months in patients with or without LD, respectively. A higher LD frequency was observed in patients receiving thoracotomy. The LD appearance time in supportive care is short. The LD frequency in patients treated with chemotherapy that revealed progressive disease was higher than the patients who revealed stable disease or objective response. LD developed in 2 months in patients with sarcomatous and mixed cell type, and the survival rate was low. LD was not associated with the stage of the disease. The most suitable candidate groups for PR are patients receiving supportive therapy, thoracotomy without multi-modal therapy or patients with sarcomatous and mixed cell type tumors.



___
Source: http://www.hubmed.org/display.cgi?uids=18304688
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

---

Looking for last minute shopping deals? Find them fast with Yahoo! Search.

Fw: Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:58 PM
Subject: Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.

[1]Lung Cancer. 2008 Feb 25;
Metintas M, Ak G, Parspour S, Yildirim H, Erginel S, Alatas F, Batırel HF, Sivrikoz C, Metintas S, Dundar E

In malignant pleural mesothelioma (MPM) patients, local dissemination (LD) of the tumor is frequently observed at the sites of intervention where diagnosis/treatment are performed. We evaluate the factors affecting LD frequency and discuss the use of PR in MPM patients. Histopathologically diagnosed 212 MPM patients who had not received PR were evaulated in terms of development of LD. Of the 212 patients, 29 received supportive therapy, 157 received chemotherapy and 26 received multi-modal therapy. The LD frequency was 13.2% for all patients. The median survival rate was 9 or 10 months in patients with or without LD, respectively. A higher LD frequency was observed in patients receiving thoracotomy. The LD appearance time in supportive care is short. The LD frequency in patients treated with chemotherapy that revealed progressive disease was higher than the patients who revealed stable disease or objective response. LD developed in 2 months in patients with sarcomatous and mixed cell type, and the survival rate was low. LD was not associated with the stage of the disease. The most suitable candidate groups for PR are patients receiving supportive therapy, thoracotomy without multi-modal therapy or patients with sarcomatous and mixed cell type tumors.



___
Source: http://www.hubmed.org/display.cgi?uids=18304688
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

---

Looking for last minute shopping deals? Find them fast with Yahoo! Search.

Fwd: Weitz & Luxenberg Stands with Petitioners against ''Ban Asbestos'' Bill (Business Wire via Yahoo! Finance)

---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Wed, Mar 5, 2008 at 1:02 AM
Subject: Weitz & Luxenberg Stands with Petitioners against ''Ban Asbestos'' Bill (Business Wire via Yahoo! Finance)
To: collegeschoolloan@gmail.com


NEW YORK----Should we continue to allow asbestos in children's toys? Should we continue to allow asbestos in the streets our children play on? The resounding answer to these questions is "No," yet the current "Ban Asbestos" Senate Bill permits these continued uses of asbestos.

Tue, 04 Mar 2008 14:45:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=11rs1vpur/*http%3A//biz.yahoo.com/bw/080304/20080304005377.html?.v=1
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc